See more : CASI Pharmaceuticals, Inc. (CASI) Income Statement Analysis – Financial Results
Complete financial analysis of Panacea Life Sciences Holdings, Inc. (PLSH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Panacea Life Sciences Holdings, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Henderson International Income Trust plc (HINT.L) Income Statement Analysis – Financial Results
- Uttam Sugar Mills Limited (UTTAMSUGAR.BO) Income Statement Analysis – Financial Results
- Spartacus Acquisition Corporation (TMTSU) Income Statement Analysis – Financial Results
- Kromek Group plc (KMK.L) Income Statement Analysis – Financial Results
- The Mission Group plc (TMG.L) Income Statement Analysis – Financial Results
Panacea Life Sciences Holdings, Inc. (PLSH)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.panacealife.com
About Panacea Life Sciences Holdings, Inc.
Panacea Life Sciences Holdings, Inc., a seed to sale cannabinoid and nutraceutical manufacturer and research company, develops and produces natural pharmaceutical alternatives for consumers and pets. The company manufactures and sells softgels, gummies, tinctures, sublingual tablets, cosmetics, and other topicals. It is also involved in the personal protection equipment (PPE) business, including importing and selling PPE hand sanitizers and masks, as well as white label and contract manufacturing sales to other cannabinoid companies, raw material sales, and tolling arrangements. The company was incorporated in 2008 and is headquartered in Greenwood Village, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.38M | 1.63M | 2.06M | 9.02M | 345.68K | 0.00 | 0.00 | 0.00 | 213.00 |
| Cost of Revenue | 6.47M | 1.23M | 1.52M | 7.02M | 2.05M | 0.00 | 0.00 | 0.00 | 20.63K |
| Gross Profit | -4.09M | 396.47K | 540.58K | 2.00M | -1.70M | 0.00 | 0.00 | 0.00 | -20.41K |
| Gross Profit Ratio | -171.48% | 24.37% | 26.25% | 22.15% | -491.92% | 0.00% | 0.00% | 0.00% | -9,583.10% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 22.10K | 300.00K | 356.08K | 369.34K | 77.34K |
| General & Administrative | 1.44M | 1.09M | 1.52M | 2.81M | 731.26K | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 17.95K | 209.25K | 377.92K | 638.63K | 254.87K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.46M | 1.09M | 1.52M | 2.81M | 8.95M | 2.14M | 1.64M | 1.23M | 289.69K |
| Other Expenses | 0.00 | 4.70M | 4.56M | 4.45M | 4.12M | 2.14M | 2.77M | 1.23M | 291.31K |
| Operating Expenses | 2.37M | 5.79M | 6.08M | 7.26M | 8.97M | 2.44M | 2.00M | 1.60M | 367.03K |
| Cost & Expenses | 7.93M | 7.03M | 7.60M | 14.28M | 11.02M | 2.44M | 2.00M | 1.60M | 368.66K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 683.24K | 2.05M | 1.11M | 1.51M | 479.11K | -464.47K | -68.57K | 0.00 | 0.00 |
| Depreciation & Amortization | 1.71M | 1.73M | 1.74M | 1.69M | 892.30K | 405.17K | 52.80K | 22.82K | 1.63K |
| EBITDA | -4.75M | -5.36M | -1.94M | -2.03M | -8.65M | -3.48M | -3.12M | -1.60M | -356.35K |
| EBITDA Ratio | -199.02% | -209.44% | -210.66% | -51.69% | -2,829.33% | 0.00% | 0.00% | 0.00% | -172,211.27% |
| Operating Income | -5.55M | -5.40M | -5.54M | -5.26M | -10.67M | -2.44M | -2.00M | -1.60M | -368.44K |
| Operating Income Ratio | -232.55% | -331.81% | -269.00% | -58.31% | -3,087.46% | 0.00% | 0.00% | 0.00% | -172,976.53% |
| Total Other Income/Expenses | -2.47M | -3.49M | 1.15M | 26.01K | 653.94K | -1.90M | -1.86M | -5.53K | 10.46K |
| Income Before Tax | -8.02M | -9.14M | -4.78M | -5.23M | -10.02M | -4.34M | -3.86M | -1.60M | -357.98K |
| Income Before Tax Ratio | -336.08% | -561.94% | -232.20% | -58.02% | -2,898.29% | 0.00% | 0.00% | 0.00% | -168,064.32% |
| Income Tax Expense | 0.00 | 1.96M | 1.34M | 1.76M | -537.47K | -161.14K | -52.52K | -22.82K | 3.00 |
| Net Income | -8.02M | -11.10M | -6.12M | -6.99M | -9.48M | -4.34M | -3.86M | -1.60M | -357.98K |
| Net Income Ratio | -336.08% | -682.14% | -297.35% | -77.57% | -2,742.81% | 0.00% | 0.00% | 0.00% | -168,064.32% |
| EPS | -0.48 | -0.75 | -0.34 | -0.41 | -7.83 | -25.49 | -25.47 | -18.68 | -156.61 |
| EPS Diluted | -0.48 | -0.75 | -0.34 | -0.41 | -7.83 | -25.49 | -25.47 | -18.68 | -156.61 |
| Weighted Avg Shares Out | 16.63M | 14.86M | 17.82M | 16.92M | 1.21M | 170.14K | 151.55K | 85.81K | 2.29K |
| Weighted Avg Shares Out (Dil) | 16.63M | 14.86M | 17.82M | 16.92M | 1.21M | 170.14K | 151.55K | 85.81K | 2.29K |
Panacea Life Sciences and Sky Wellness Enter Agreement for Licensing, Marketing, Supply and Development of Sky Wellness CBD Products
GOLDEN, Colo., May 16, 2024 (GLOBE NEWSWIRE) -- Panacea Life Sciences Holdings, Inc. (OTCQB: PLSH) (“Panacea Life Sciences,” “PLSH” or the “Company”), a Colorado-based manufacturing, research and product development company in the natural health and wellness industry, announces the execution...
Panacea Life Sciences Holdings, Inc. Completes Acquisition of N7 Enterprises With Eight Natural Health and Wellness Retail and One Distribution Center Locations in the Tampa, Florida area
GOLDEN, Colo., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Panacea Life Sciences Holdings, Inc. (OTCQB: PLSH) (“Panacea” or the “Company”), a plant-based natural health ingredient and product company, today announced it has acquired eight retail locations and one distribution center in...
Panacea Life Sciences Holdings, Inc. Continues Growth Trajectory with Acquisition of the PÜR LIFE Medical Franchise
The company expands upon its vertical integration vision within the alternative remed ies and therap ies space.
Panacea Life Sciences Holdings, Inc. Celebrates National CBD Day (August 8th) By Shifting To An “Everyday Low Pricing Model” To Meet Customer Needs
T he new pricing model for Panacea's natural health & wellness products will not only help customers afford natural remedies in this strained economy but will provide consistency and a promise that is better aligned with the company's vision to...
Panacea Life Sciences Holdings, Inc. Continues Pursuit of High Growth Health and Wellness Products with Acquisition of Sierra Sage, LLC and Halucenex from Melodial Global Health (formerly Creso Pharma Limited)
Golden, Colorado, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Panacea Life Sciences Holdings, Inc. (OTCQB:PLSH) ("Panacea” or the "Company"), today announced it has entered into a Letter of Intent with Melodial Global Health (formerly Creso Pharma) to acquire Sierra Sage Herbs...
Panacea Life Sciences Holdings, Inc. Announces CBD/CBG Clinical Trial Findings for the Management of Irritable Bowel Symptoms
GOLDEN, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- Panacea Life Sciences Holdings, Inc. (OTCQB:PLSH) (“Panacea” or the “Company”), a plant-based natural health and wellness company, today announced it will be presenting its positive findings from open label clinical trial on...
Panacea Life Sciences Holdings, Inc. Chief Scientific Officer, Dr. James Baumgartner, is Featured on The Stock Day Podcast
PHOENIX, AZ / ACCESSWIRE / July 18, 2023 /Phoenix, Arizona The Stock Day Podcast welcomed Panacea Life Sciences Holdings, Inc. (PLSH)("the Company"), a holding company structured to develop and facilitate manufacturing, research, product development and distribution in the high-growth, natural...
Panacea Life Sciences Holdings, Inc. Chief Scientific Officer, Dr. James Baumgartner, is Featured on The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - July 18, 2023) - The Stock Day Podcast welcomed Panacea Life Sciences Holdings, Inc. (OTCQB: PLSH) ("the Company"), a holding company structured to develop and facilitate manufacturing, research, product development and distribution in the high-growth, natural...
Panacea Life Sciences Holdings, Inc. Enters Into Agreement to Natural Health and Wellness Chain of Retail Locations in Tampa, Florida
GOLDEN, Colo., July 10, 2023 (GLOBE NEWSWIRE) -- Panacea Life Sciences Holdings, Inc. (OTCQB: PLSH) (“Panacea” or the “Company”), a plant-based natural health ingredient and product company, today announced it has entered into agreements to acquire eight retail locations in...
Panacea Life Sciences Holdings, Inc. Adopts Diversification Plan: Vegan, Organic, Nutraceuticals, Alternative Health and Wellness Products and Investigative Research Plans for Psylocibin and other Psychedelics.
GOLDEN, Colo., July 07, 2023 (GLOBE NEWSWIRE) -- Panacea Life Sciences Holdings, Inc. (OTCQB: PLSH) (“Panacea” or the “Company”), a plant-based natural health ingredient and product company, today announced expansion plans that target natural health and wellness across a broad...
Source: https://incomestatements.info
Category: Stock Reports